We describe 2 patients with minimal-change glomerulopathy (MCG) associated with an undifferentiated carcinoma of unknown origin and urothelial carcinoma. Oliguric acute renal failure and histopathological changes consistent with acute tubular necrosis were also observed. Fourteen other cases of MCG complicating solid tumors reported in the literature are reviewed. MCG should be included in the nephropathies which cause nephrotic syndrome in adult patients with carcinoma.
Objectives: The Netherlands has recently started with the stepwise implementation of biennial faecal immunochemical testing for colorectal cancer (CRC). We evaluated the impact of the transition to, and the fully implemented screening programme on the long-term CRC incidence and colonoscopy demand. MethOds: The previously reported and calibrated ASCCA model was set up to simulate the Dutch CRC screening programme between 2014 and 2044. We adopted an open-model approach by simulating multiple birth cohorts and combining the results while accounting for the ageing of the population. Besides a no screening scenario, we evaluated the impact of screening under three sets of natural history assumptions which differed in the contribution of the serrated pathway to the CRC incidence (0%, 15% and 30%). Model-predicted outcomes were CRC incidence and colonoscopy demand per year. Results: Due to ageing, the model-predicted CRC incidence in the no screening scenario increased from 77/100,000 in 2014 to 109/100,000 in 2044. Under screening, the predicted CRC incidence in 2014 was between 105/100,000 (assuming all CRCs originate from adenomas) and 109/100,000 (assuming that 30% of CRCs arises from serrated lesions) due to the detection of asymptomatic, prevalent tumours. After this peak, the predicted incidence gradually decreased until in 2039 a new equilibrium was reached, ranging between 65/100,000 and 71/100,000 assuming that 100% versus 70% of CRCs originate from adenomas, respectively. Due to the stepwise implementation, the predicted number of colonoscopies required for the screening programme increased gradually over time from 38,000 (752,199 invitees) in 2014 to 117,000 (2,154,875 invitees) in 2044. cOnclusiOns: The Dutch screening programme will markedly decrease CRC incidence in the next 25 years. The conclusions about the impact of screening were robust to key natural history assumptions. With the results of this study, decision-makers can anticipate the expected change in CRC-related health care use and colonoscopy demand.
Background: While the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines advise exercise to reduce disease progression, little investment in promoting physical activity (PA) is made by health care authorities. The purpose of this study was to estimate the cost-effectiveness of regular PA vs sedentary lifestyle in people with COPD in the UK. Methods: Efficacy, quality of life, and economic evidence on the PA effects in COPD patients were retrieved from literature to serve as input for a Markov microsimulation model comparing a COPD population performing PA vs a COPD population with sedentary lifestyle. The GOLD classification defined the model health states. For the base case, the cost of PA was estimated at zero, a lifetime horizon was used, and costs and effects were discounted at 3.5%. Analyses were performed from the UK National Health Service (NHS) perspective. Uncertainty around inputs and assumptions were explored via scenario and sensitivity analyses, including a cost threshold analysis. Outcomes were cost/quality-adjusted life year (QALY) gained and cost/year gained. Results: Based on our model, the effects of PA in the UK COPD population would be lower mortality (-6%), fewer hospitalizations (-2%), gains in years (+0.82) and QALYs (+0.66), and total cost savings of £2,568. The cost/QALY and cost/year gained were dominant. PA was costsaving at costs ,£35/month and cost-effective at cost ,£202/month. The main model drivers were age and PA impact on death and hospital-treated exacerbations. Conclusion: Including PA in the management of COPD leads to long-term clinical benefits. If the NHS promotes only exercise via medical advice, this would lead to health care cost savings. If the NHS chose to fund PA, it would still likely be cost-effective.
and retrieved from an extra boost of ONCOVIEW database. ONCOVIEW is a continuous syndicated study on cancer treatment in the hospital setting, based on the collection of patient questionnaires. Patients inclusion criteria were the presence of an mCRC diagnosis, 3rd or later actual therapy line and no participation in a phase II or III clinical study. Information collected included patient demographic characteristics, mCRC characteristics (TNM Classification, Karnofsky performance status scale and mutation analyses) and treatments (actual and previous schedules, dosages and durations). Furthermore, an evaluation of the "Rechallenge" occurrence, in other words the use in 3rd or later line of treatment of drugs previously used, has been performed. Results: 261 patients diaries have been collected: 218 out of 261 patients were in third line of treatment, while 43 patients were in 4th or later treatment line. The most administered schema among third line patients was Capecitabine alone (63 patients), while the most used schema in fourth line was a combination of Fluorouracil and Folinic Acid (7 patients). About 40% of molecules administered in 3rd line and 67% of molecules administered in 4th line were used in previous lines. ConClusions: Results from the present study underline the unmet medical need in 3rd or later line of treatment of mCRC patients and the need for additional evidence-based treatment options.objeCtives: The objective of this study was to assess the oncologists' real clinical practice in the management of mCRC patients, with a focus on the 3rd, 4th and later lines of therapy in Italy. Methods: Data presented in this study were collected from medical records obtained by Italian oncologists on mCRC patients
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.